Search / Trial NCT00002190

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Launched by HOFFMANN-LA ROCHE · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Drug Therapy, Combination Zidovudine Hiv Protease Inhibitors Lamivudine Saquinavir Reverse Transcriptase Inhibitors Anti Hiv Agents

ClinConnect Summary

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV antibody positive.
  • CD4 count \>= 150 and \<= 500 cells/mm3.
  • Exclusion Criteria
  • Prior Medication:
  • Excluded:
  • Prior antiretroviral therapy.
  • Prior protease inhibitor therapy.

About Hoffmann La Roche

Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.

Locations

New York, New York, United States

San Francisco, California, United States

Sherman Oaks, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials